Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 15/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TPI1 | P60174 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748800 | 0.91 | PARP1 (0.45) | ENPP1PARP1PARP2TUBB4ATUBB | |
| SCHEMBL19747935 | 0.90 | PARP1 (0.43) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL30089694 | 0.90 | PARP1 (0.43) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19748554 | 0.89 | CYP3A4 (0.52) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL30089587 | 0.89 | CYP3A4 (0.52) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19747642 | 0.88 | PARP1 (0.41) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19748874 | 0.88 | PARP1 (0.44) | ENPP1TSHRPARP1PARP2TUBB4A | |
| SCHEMBL19748244 | 0.87 | PARP1 (0.43) | PARP1PARP2TUBB4ATUBBTUBA3C | |
| SCHEMBL19748384 | 0.87 | AR (0.52) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL29655130 | 0.87 | AR (0.52) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3475272-B1 | PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11072600-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| US-10640493-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190352283-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190337928-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2019-11-07 | — | — | US | disclosed |
| EP-3475272-A1 | PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER | The Regents of The University of California (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223516-A1 | PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | ENPP1 1493/4885CYP3A4 3102/4885CYP2C9 4189/4885 |
| US-20190337928-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | ENPP1 1493/4885CYP3A4 3102/4885CYP2C9 4189/4885 |
| US-10640493-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | ENPP1 1334/4885CYP3A4 3698/4885CYP2C9 4661/4885 |
| US-11072600-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | ENPP1 1493/4885CYP3A4 3102/4885CYP2C9 4189/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | ENPP1 1493/4885CYP3A4 3102/4885CYP2C9 4189/4885 |
| US-20190352283-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | ENPP1 1334/4885CYP3A4 3698/4885CYP2C9 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.